CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 227 enrolled / 227 target
Drug / intervention
JNJ-77242113drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05364554
NCT05364554Phase 2CompletedMonitor (4.7/mo)Completion was 33mo ago
CompareCT.gov

A Phase 2b Multicenter, Long-Term Extension, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis

Janssen Research & Development, LLC·interventional·Posted May 6, 2022·Updated Jun 1, 2026

In Brief

A Phase 2 clinical trial evaluating JNJ-77242113 for Plaque Psoriasis. Completed, enrolled 227 participants across 60 sites in 10 countries.

Signals

Enrolling slower than its timeline implies

Detailed Summary

The purpose of this study is to evaluate long-term clinical response of JNJ-77242113 treatment in participants with moderate-to-severe plaque psoriasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesCanada, France, Germany, Japan, Poland, South Korea, Spain, Taiwan, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedMay 6, 2022
Enrollment StartJun 10, 2022
Primary CompletionSep 29, 2023
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 4.2 years ago

Arms & Interventions

Group 1: JNJ-77242113 Dose 1 Once Daily (QD)experimental

Participants originally randomized to JNJ-77242113 Dose 1 QD in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 1 QD from Week 0 through Week 36 in this study.

Drug: JNJ-77242113
Group 2: JNJ-77242113 Dose 2 QDexperimental

Participants originally randomized to JNJ-77242113 Dose 2 QD in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 2 QD from Week 0 through Week 36 in this study.

Drug: JNJ-77242113
Group 3: JNJ-77242113 Dose 3 QDexperimental

Participants originally randomized to JNJ-77242113 Dose 3 QD in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 3 QD from Week 0 through Week 36 in this study.

Drug: JNJ-77242113
Group 4: JNJ-77242113 Dose 1 Twice Daily (BID)experimental

Participants originally randomized to JNJ-77242113 Dose 1 BID in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 1 BID from Week 0 through Week 36 in this study.

Drug: JNJ-77242113
Group 5: JNJ-77242113 Dose 3 BIDexperimental

Participants originally randomized to JNJ-77242113 Dose 3 BID in originating study 77242113PSO2001 will continue to receive JNJ-77242113 Dose 3 BID from Week 0 through Week 36 in this study.

Drug: JNJ-77242113
Group 6: JNJ-77242113 Dose 3 QDexperimental

Participants originally randomized to placebo in originating Study 77242113PSO2001 will receive JNJ-77242113 Dose 3 QD from Week 0 through Week 36 in this study.

Drug: JNJ-77242113

Interventions

JNJ-77242113drug

JNJ-77242113 tablet will be administered orally.